• Eyam Health, a Canadian biotech, teams with Medicines for Malaria Venture (MMV) to develop affordable, long-lasting monoclonal antibody therapies

• Partnership harnesses Eyam’s AI-powered Jennerator platform and Gemini delivery system, enabling multiple antibodies in one durable, cold-chain-free dose

• Aims to simplify malaria prevention in resource-limited settings and tackle drug resistance with a potential single injection covering an entire malaria season

Eyam Health and MMV announce a strategic partnership to develop next-generation monoclonal antibody-based malaria therapies that promise to revolutionize prevention efforts in sub-Saharan Africa and beyond.

Malaria remains a massive global health and economic burden, causing nearly 600,000 deaths and over 250 million cases annually — disproportionately affecting children and pregnant women. Current tools like bed nets and vaccines are vital but have limitations, especially amid rising drug resistance.

Eyam Health’s advanced biologics technology combines two powerful platforms: Jennerator, an AI engine rapidly designing novel therapies, and Gemini, a next-generation delivery system enabling multiple antibodies to be combined in a single, long-lasting dose without cold storage. This could protect millions from malaria during the entire rainy season with a single injection costing less than $1.

Dr Brice Campo, MMV’s senior director of Biology and Novel Technologies, said, “This collaboration marks a major step toward innovative, affordable monoclonal antibodies with longer dosing intervals, potentially transforming large-scale malaria prevention campaigns.”

Unlike traditional monoclonal antibody approaches, which are costly and complex, Gemini’s nucleic acid-based technology bypasses expensive lipid nanoparticles and supports local manufacturing scalability in Africa, enhancing accessibility and pandemic preparedness.

Dr Wilf Jefferies, Eyam Health’s chief scientific officer, added, “Our partnership with MMV validates the transformative potential of our technologies, positioning Eyam at the forefront of next-gen infectious disease therapeutics. This is a paradigm shift in global health innovation.”

Together, Eyam Health and MMV are committed to delivering effective, economically viable healthcare solutions that could accelerate malaria elimination and improve millions of lives.